{"filing":{"accession_number":"0001193125-26-264047","cik":"0001579428","ticker":"AXSM","company_name":"Axsome Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"axsm-20260605.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526264047/axsm-20260605.htm"},"events":[{"id":5939,"run_id":5212,"accession_number":"0001193125-26-264047","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Compensation Committee approved adoption of a new Executive Severance and Change in Control Plan effective June 5, 2026, which establishes severance and change-in-control benefits for named executive officers and other key employees. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The plan specifies tiered severance payments, equity acceleration, and COBRA benefits triggered by qualifying termination events, making it material to investor assessment of executive compensation obligations.","company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","filing_date":"2026-06-09","submitted_at":null,"items":[{"id":5649,"accession_number":"0001193125-26-264047","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Compensation Committee approved adoption of a new Executive Severance and Change in Control Plan effective June 5, 2026, which establishes severance and change-in-control benefits for named executive officers and other key employees. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The plan specifies tiered severance payments, equity acceleration, and COBRA benefits triggered by qualifying termination events, making it material to investor assessment of executive compensation obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T21:22:08.309331+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5649,"accession_number":"0001193125-26-264047","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Compensation Committee approved adoption of a new Executive Severance and Change in Control Plan effective June 5, 2026, which establishes severance and change-in-control benefits for named executive officers and other key employees. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The plan specifies tiered severance payments, equity acceleration, and COBRA benefits triggered by qualifying termination events, making it material to investor assessment of executive compensation obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T21:22:08.309331+00:00","company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","filing_date":"2026-06-09"}]}